The iPSCs generated from JMML harboring PTPN11 or CBL mutation have differential responses to the MEK inhibitors and JAK inhibitors owing to the activation of specific signaling pathways [70]. Here, MAP2K7 is linked to juvenile myelomonocytic leukemia.